Aims: Two unmet therapeutic strategies for diabetes treatment are prevention of beta-cell death and stimulation of beta-cell replication. Our aim was to characterize the role of neuropeptide Y receptors in the control of beta-cell mass.
defined. [12] [13] [14] In the foetus it is expressed in the earliest-formed islet endocrine cells, 15, 16 suggesting a role in islet development. However, in the adult pancreas, PYY production is restricted to subpopulations of α-, δ-and pancreatic polypeptide (PP)-cells. 13, 17 A large body of evidence suggests that activation of islet NPY receptors inhibits insulin secretion both in vitro and in vivo. NPY and PYY1-36 have been shown to inhibit stimulated insulin secretion from isolated islets in a number of species. 18, 19 In vivo intravenous administration of PYY1-36 inhibits insulin secretion 13 and PYY knockout mice are hyperinsulinaemic. 20 In contrast, PYY3-36 has no effect on insulin secretion, consistent with the absence of Y2R expression in islets. 21 In addition to the reported effects of NPY receptors on the regulation of insulin secretion, it is becoming apparent that these receptors could be targets for the preservation of beta-cell mass. Our previous data suggest that PYY may provide an anti-apoptotic tone helping to maintain beta-cell mass. 1 Additionally, NPY receptor activation in other cell types protects against apoptosis 22 and, more recently, their activation has tentatively revealed anti-apoptotic and mitotic potentials in insulin-producing cells, albeit in transformed clonal cell lines. 23 Together, these data point to NPY receptor signalling being a prime candidate for further investigation, as a target for the maintenance of beta-cell mass. To this end, we investigated the role of NPY receptor activation using endogenous and selective agonists on beta-cell mass in isolated primary islets and in a whole-animal model of diabetes. 
| METHODS

| Islet isolation
Mouse islets were isolated from male CD1 mice aged 8-12 weeks (Charles River Laboratories, Margate, UK) by collagenase digestion
(1 mg/mL; type XI; Sigma-Aldrich, Poole, UK) and separated on a histopaque gradient (Histopaque 1077; Sigma-Aldrich). 24 Human islets were obtained from the pancreata of non-diabetic heart-beating donors with appropriate ethical approval. 25 All islets were incubated overnight at 37 C (5% CO 2 ) prior to experiments.
| qPCR
Total RNA was extracted from approximately 200 islets using an RNAeasy kit (Qiagen, Sussex, UK). Reverse transcription was performed using the High-capacity cDNA Reverse Transcription kit (Applied Biosystems, Warrington, UK). Quantitative PCR amplification was performed as previously described. 26 A list of primers used can be found in the Supporting Information figures. 
| Islet apoptosis in vitro
| Nuclear NFkB and nitrite production
Groups of 50 islets (n = 4) were cultured for 48 hours in RPMI in the absence or presence of a cytokine cocktail (IL-1β, 1 ng/mL; TNF-α, ]-NPY. Nitrite production in the culture media was measured using the Measure-iT High Sensitivity Nitrite Assay Kit (Molecular Probes). NFkB p65 in nuclear extracts was measured using an Elisa (Abcam, Cambridge, UK).
| In vitro islet proliferation
Islets were cultured in RPMI (2% FBS, 1% penicillin-streptomycin, 1%
l-glutamine) containing 1 mg/mL BrdU, with the addition of 10 nM 
| Data analysis
Data are expressed as mean AE SEM and were analysed using one-or two-way ANOVA as appropriate, and Bonferroni's post-hoc test or t-tests where only 2 groups were compared. A P value <.05 between treatments was considered significant.
3 | RESULTS
| Expression of NPY receptors in mouse and human islets
It has been reported that mouse and human islets express the Y1R and Y4R, while human islets additionally express the Y5R, and neither express the Y2R. 18, 26, 28 Next-generation sequence of specific islet cell types has somewhat confused this picture. In mouse, RNAseq of beta, alpha and delta cells suggests that only the Y1R is expressed at detectable levels and it was expressed in all cell types. 29, 30 However, data from sorted human alpha and beta cells suggest that all NPY receptor subtypes are present in all cell types. 31 We confirmed the expression of NPY receptors in islets from CD1 male mice and in human islets. The Y1R receptor was the most abundantly expressed NPY receptor subtype in mouse and human islets. The Y4R was expressed at low levels in both species, while the Y5R was additionally expressed in human islets but not by mouse tissue, and the Y2R receptor was not detectable in either species ( Figure S1 ). The receptor expression levels were variable; this could be indicative of the presence of pancreatic neuronal ganglia, which may express NPY receptors, in some islet preparations.
| Islet NPYR activation protects islets from cytokine-induced apoptosis
Our previous data suggested that PYY signalling may provide trophic support to beta-cells, and either the Y1R or Y2R were the most likely receptors through which this occurred. 1 To further explore the protective role of NPY receptors, we investigated the potential of endogenous and selective agonists to prevent apoptosis in islets exposed to a cocktail of cytokines designed to approximate the toxic cytokine milieu evident during diabetes. Subsequently, we measured caspase 3/7 activity as a surrogate marker of apoptosis. The selectivity of the ligands was determined using cAMP assays against NPY receptor subtypes (Figure 2A,B) . Together, the data demonstrate that islet-expressed NPYRs are functionally conserved with respect to their ability to protect islet cell types from cytokine-induced injury.
| Islet NPYR activation rescues glucose responsiveness in islets following injury
To establish whether the protective effect of NPYR agonism could maintain the insulin secretory function of islets, we performed static insulin secretion studies following cytokine treatment. We empirically determined a less aggressive cytokine cocktail to allow us to more sensitively determine insulin secretion in these functional studies ( Figure S3 ).
As expected, cytokine exposure completely impaired insulin secretion in response to 20 mmoL/L glucose ( Figure 2C,D) . This impaired secretory in both mouse and human islets, demonstrating that islet Y receptor activation functionally protects islets from injury. ]-NPY protected islets from cytokine-induced apoptosis by coupling to Gαi, as pertussis toxin significantly attenuated its protective effects ( Figure 2E,F) . To determine whether islet NPYRs engage intracellular kinases, we used the non-specific inhibitor staurosporine, which blocked [Leu ]-NPY for 48 hours, in the absence or presence of a cytokine cocktail for the last 20 hours. Following treatment, groups of islets underwent static secretion assays. *P < .05, **P < .01, ***P < .001 vs 2 mmoL/L glucose, one-way ANOVA and Bonferroni's multiple comparisons test. Data are presented as mean AE SEM, n = 8 observations per treatment group. E-J, Islets were treated for 48 hours with 1 nM [Leu 31 Pro 34 ]-NPY, in the absence or presence of 100 ng/mL pertussis toxin (E and F), 10 μM U73122 (G and H) or 1 μM Go6983 (I and J). **P < .01, ***P < .001 vs control, Δ P < .05, ΔΔ P < . ]-NPY, oneway ANOVA and Bonferroni's multiple comparisons test. Data are presented as mean AE SEM, n = 6 biological replicates per treatment group FIGURE 3 The anti-apoptotic effects of Y4R and Y5R are also mediated via a Giα-PLC-PKC pathway. Islets were treated for 48 hours with 1 nM Y141 (Y4R agonist), in the absence or presence of: A and B, 100 ng/mL pertussis toxin; C and D, 10 μM U73122; or E and F, 1 μM Go6983. Islets were treated with BWX46, a Y5R agonist, in the presence of: G, pertussis toxin; H, U73122; or I, Go6983. J, Islets were treated with Y141 for 48 hours, in the absence or presence of a cytokine cocktail for the last 20 hours. Following treatment, groups of islets underwent static insulin secretion assays. **P < .01, ***P < .001 vs control, Δ P < .05, ΔΔ P < .01, ΔΔΔ P < .001 vs cytokines, ++ P < .01, +++ P < .001 vs treatment, one-way ANOVA and Bonferroni's multiple comparisons test. Data are presented as mean AE SEM, n = 6 biological replicates per treatment group H, Representative images of TUNEL (blue/black) and inuslin (red) co-localization. *P < .05, **P < .01, ***P < .001 vs. 2 mmoL/L glucose. ***P < .001 vs control, ΔΔ P < .01, ΔΔΔ P < .001 vs cytokines, one-way ANOVA and Bonferroni's multiple comparisons test. *P < .05, **P < .01, Δ P < .01 vs STZ group, two-way repeated measures ANOVA and Bonferroni's multiple comparisons test. Data are presented as mean AE SEM, (n = 8) effects ( Figure S4 ). Subsequently, we sought to determine which kinases were involved. Protection against injury was blocked by the PLC inhibitor U73122 ( Figure 2G,H) , by PKC depletion with PMA ( Figure S4 ) and by the PKC inhibitor Go6983 ( Figure 2I ,J), demonstrating the protective effect of NPYR activation signals via PLC and PKC downstream of Gαi engagement in both mouse and human islets. Similarly, we found that the protective effects of both the Y4R agonist (mouse and human islets) and the Y5R agonist (human islets) could be blocked by pertussis toxin, U73122 and Go6983 ( Figure 3A-I ).
| How does islet NPYR activation prevent apoptosis in islets?
To further elucidate the mechanisms of the anti-apoptotic effect, we measured expression of genes involved in the regulation of apoptosis.
As expected, the anti-apoptotic gene Bcl-2 was downregulated in response to cytokines, and [Leu and by increasing mitochondrial pro-survival signalling ( Figure 4I ).
| Islet NPYR activation induces beta cell proliferation
Strategies designed to maintain beta-cell mass are likely to be more successful if they target more than one mechanism, for example, protecting beta-cells from injury while also increasing proliferation. We 
| Islet NPYR activation protects islets from injury in vivo
If the islet NPYRs are to be considered novel targets for the maintenance of beta-cell mass, it is critical to demonstrate efficacy in vivo.
To selectively target the NPYRs expressed by the islet, and not the PYY1-36 is a non-selective receptor agonist that circulates at concentrations that may activate islet NPY receptors. It is produced and released locally in the islet. 21, 38 NPY, another non-selective agonist 18 that is released into the islet via nerve endings, 39 has also been suggested to be produced and released by beta-cells 40 and circulates in concentrations similar to those of PYY. Furthermore, pancreatic polypeptide, a selective Y4R agonist (100-fold over Y5R), is also produced locally in the islet. [41] [42] [43] As NPY receptors appear to be pharmacologically conserved, future tissue-specific and receptorspecific knockout experiments, designed to tease apart the relative importance of each ligand, to determine whether a locally produced or circulating source plays a role, and to understand the collective or individual contribution of each receptor, will help to clarify the physiological role of this system in the protection of the islet from injury.
As we used whole islets, we could not determine whether the and Y5R are functionally present and, in the case of Y1R and Y5R, the effects can be blocked with selective antagonists. These functional readouts would be further strengthened by using islets from mice with targeted deletion of each receptor.
There are clearly many questions to be answered with regard to the physiological role of the PYY/NPY system in the control of beta-cell mass, but our in vitro data do suggest that targeting these receptors pharmacologically could preserve beta-cell mass in diabetes. Our lipi- perhaps more important, Y1R causes vasoconstriction, 48 both undesirable side effects when treating metabolic diseases. Therefore, any strategy targeting NPYRs will probably require islet specificity or delivery, in combination with compounds that alleviate the inherent drawbacks. Despite these caveats, NPYR activation displays a remarkable capacity to protect human islets from injury.
